PMID- 15940146
OWN - NLM
STAT- MEDLINE
DCOM- 20050802
LR  - 20061115
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 115
IP  - 6
DP  - 2005 Jun
TI  - Brain-derived neurotrophic factor is increased in atopic dermatitis and modulates 
      eosinophil functions compared with that seen in nonatopic subjects.
PG  - 1268-75
AB  - BACKGROUND: Recently, the pivotal role of brain-derived neurotrophic factor 
      (BDNF) has been described in allergic asthma. However, the role of this 
      neurotrophin in atopic dermatitis (AD) still remains unknown. OBJECTIVE: The aim 
      of this study was to investigate the functional role of BDNF on eosinophils and 
      to assess BDNF levels in patients with AD and nonatopic control subjects. Methods 
      p75 Neurotrophin receptor and tyrosine kinase B receptor expression was 
      demonstrated by using FACS analysis and immunohistochemistry. BDNF levels were 
      assessed with ELISA and FACS analysis. Chemotactic activity (modified Boyden 
      chamber assay), eosinophil cationic protein release (fluoroenzyme immunoassay), 
      respiratory burst (lucigenin-dependent chemiluminescence), and apoptosis 
      (Nicoletti protocol and Annexin-V method) assays were used to assess BDNF 
      functional activity. RESULTS: BDNF levels were increased in serum, plasma, 
      eosinophils, and supernatants of stimulated eosinophils from patients with AD 
      compared with levels seen in nonatopic control subjects ( P < .05-.001). In 
      addition, p75 neurotrophin receptor and tyrosine kinase B expression was higher 
      on eosinophils from patients with AD compared with that seen on eosinophils from 
      nonatopic control subjects ( P < .05-.001). Eosinophil apoptosis was inhibited by 
      BDNF ( P < .05-.01) and chemotactic index was increased ( P < .001) in 
      BDNF-stimulated eosinophils from patients with AD, whereas this effect was not 
      shown in eosinophils from nonatopic control subjects. However, no response of 
      BDNF through the release of eosinophil cationic protein or reactive oxygen 
      species was found. CONCLUSION: This study provides the first evidence for a 
      functional role of BDNF on eosinophils from patients with AD, probably mediated 
      by an increased expression of BDNF receptors compared with that seen in nonatopic 
      control subjects. In addition, higher intracellular, serum, and plasma BDNF 
      levels, as well as the release of BDNF by eosinophils, underline the particular 
      importance of BDNF in patients with AD, pointing to new pathophysiologic aspects 
      of this chronic inflammatory skin disease.
FAU - Raap, Ulrike
AU  - Raap U
AD  - Department of Dermatology and Allergology, Hannover Medical University, 
      Ricklingerstrasse 5, 30449 Hannover, Germany. mail@ulrike-raap.de
FAU - Goltz, Christine
AU  - Goltz C
FAU - Deneka, Nicole
AU  - Deneka N
FAU - Bruder, Manuela
AU  - Bruder M
FAU - Renz, Harald
AU  - Renz H
FAU - Kapp, Alexander
AU  - Kapp A
FAU - Wedi, Bettina
AU  - Wedi B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Culture Media, Conditioned)
RN  - 0 (Receptor, Nerve Growth Factor)
RN  - 0 (Receptors, Nerve Growth Factor)
SB  - IM
MH  - Apoptosis
MH  - Brain-Derived Neurotrophic Factor/blood/*metabolism
MH  - Cells, Cultured
MH  - Chemotaxis
MH  - Culture Media, Conditioned
MH  - Dermatitis, Atopic/blood/*immunology/*metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Eosinophils/*immunology/metabolism
MH  - Flow Cytometry
MH  - Humans
MH  - Receptor, Nerve Growth Factor
MH  - Receptors, Nerve Growth Factor/metabolism
MH  - Time Factors
MH  - Up-Regulation
EDAT- 2005/06/09 09:00
MHDA- 2005/08/03 09:00
CRDT- 2005/06/09 09:00
PHST- 2005/06/09 09:00 [pubmed]
PHST- 2005/08/03 09:00 [medline]
PHST- 2005/06/09 09:00 [entrez]
AID - S0091674905003581 [pii]
AID - 10.1016/j.jaci.2005.02.007 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2005 Jun;115(6):1268-75. doi: 10.1016/j.jaci.2005.02.007.